Results 71 to 80 of about 1,093 (174)

Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives

open access: yesNature and Science of Sleep, 2021
Vivien C Abad Department of Psychiatry & Behavioral Sciences, Division of Sleep Medicine, Stanford University, Redwood City, CA 94063, USACorrespondence: Vivien C AbadDepartment of Psychiatry & Behavioral Sciences Division of Sleep Medicine ...
Abad VC
doaj  

Narcolepsy: Pathophysiology, Diagnosis, Management, and Future Directions, a Narrative Review

open access: yesBrain and Behavior, Volume 15, Issue 12, December 2025.
This visual summary outlines the pathophysiology of narcolepsy, driven by hypocretin loss, and details its clinical diagnosis, current management strategies, and the shift toward future disease‐modifying therapies like orexin agonists and immunomodulation.
Natasha Elaine Hastings   +12 more
wiley   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: G protein‐coupled receptors

open access: yesBritish Journal of Pharmacology, Volume 182, Issue S1, Page S24-S151, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander   +206 more
wiley   +1 more source

Recent advances in narcolepsy

open access: yesAdvances in Clinical Neuroscience & Rehabilitation, 2016
Narcolepsy is thought to affect 0.05% of Caucasian populations and frequently causes severe symptoms across the 24-hour period. It is best viewed as a disorder of sleep-wake regulation with particular abnormalities of the rapid eye movement (REM ...
Paul Reading
doaj   +1 more source

New developments in the management of narcolepsy

open access: yesNature and Science of Sleep, 2017
Vivien C Abad, Christian Guilleminault Department of Psychiatry and Behavioral Sciences, Division of Sleep Medicine, Stanford University Outpatient Center, Redwood City, CA, USA Abstract: Narcolepsy is a life-long, underrecognized sleep disorder ...
Abad VC, Guilleminault C
doaj  

Efficacy of Pitolisant 20 mg in Reducing Excessive Daytime Sleepiness and Fatigue in Patients with Obstructive Sleep Apnoea Syndrome: An Individual Patient Data Meta-analysis

open access: yes, 2022
BACKGROUND AND OBJECTIVE: Excessive daytime sleepiness (EDS) and fatigue are major complaints in patients with obstructive sleep apnoea (OSA) syndrome. Pitolisant is an orally active selective histamine H3 receptor (H3R) antagonist/inverse agonist, which
Lehert, P
core   +1 more source

Pitolisant nanofibers: A promising frontier in drug delivery for narcolepsy - Formulation, optimisation, and characterization insights

open access: yesBiomedical Technology
The study focuses on developing a new way to deliver the narcolepsy medication pitolisant. Electrospinning was used to make polyvinyl alcohol (PVA) and hyperbranched polyglycerol (HPG) polymers into pitolisant nanofibers (PT-NF).
J. Nandhini   +5 more
doaj   +1 more source

Utilizing quality by design methodology for liquid chromatography method development and validation in quantifying impurities in Pitolisant, a Histamine-3 (H3) receptor antagonist/inverse agonist

open access: yesResults in Chemistry
We developed and validated a liquid chromatography technique to determine organic impurities of Pitolisant in Pitolisant film-coated tablets (4.45 mg and 17.8 mg), a medication used to treat excessive daytime drowsiness.
Jayaprakash Kanijam Raghupathi   +6 more
doaj   +1 more source

Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial

open access: yes, 2023
BACKGROUND: Narcolepsy is a life-long disorder characterised by excessive daytime sleepiness and cataplexy, often arising in childhood or adolescence. Pitolisant, a selective histamine H3 receptor inverse agonist, has been approved in Europe and USA for ...
Lehert, P   +10 more
core   +1 more source

Treatment of narcolepsy and pregnancy: a review

open access: yesSleep Science and Practice
This is a chapter review of pregnancy state in patients with narcolepsy which aims to provide a review of literature regarding pregnancy in patients with narcolepsy, physiology of hormonal change during pregnancy on sleep, pharmacologic and non ...
Kullatham Kongpakpaisarn, Christine Won
doaj   +1 more source

Home - About - Disclaimer - Privacy